The role of the semi natural cycle as option of treatment of patients with a poor prognosis for successful in vitro fertilization;La place du cycle semi-naturel dans la prise en charge de patientes ayant un mauvais pronostic en fécondation in vitro

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 33, Issue 6 I, 2004, Pages 518-524

  Castelo Branco, A ^a   Frydman, N ^a   Kadoch, J ^a   Le Du, A ^a   Fernandez, H ^a   Fanchin, R ^a   Frydman, R ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

AOS; COH; IMF; IVF; Semi natural cycle

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTIMA GE; ESTROGEN; FOLLITROPIN; GONADORELIN ANTAGONIST; GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; PROGESTERONE;

ALTERED OVARIAN STATUS; ARTICLE; CLINICAL TRIAL; CONTROLLED OVARIAN HYPERSTIMULATION; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; IMPLANTATION; IMPLANTATION FAILURE; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; OOCYTE; OOCYTE RECOVERY RATE; OVARY CYCLE; OVARY HYPERSTIMULATION; PROGNOSIS; SEMI NATURAL CYCLE;

EID: 5744236803     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0368-2315(04)96565-9     Document Type: Article

References (40)

1. Steptoe PC, Edwards RG. Birth after the reimplantation of a human embryo. Lancet 1978; 7: 366.
2. Ben-Rafael Z, Bider D, Dan U, Zolti M, Levran D, Mashiach S. Combined gonadotropin releasing hormone agonist/human menopausal gonadotropin therapy (GnRHa/hMG) in normal, high, and poor responder to hMG. J In Vitro Fert Embryo Transf 1991; 8: 33-6.
3. Bassil S, Godin PA, Donnez J. Outcome of in-vitro fertilization through natural cycles in poor responders. Hum Reprod 1999; 14: 1262-5.
4. Feldman B, Seidman DS, Levron J, Bider D, Shulman A, Shine S. et al. In vitro fertilization following natural cycles in poor responders. Gynecol Endocrinol 2001; 15: 328-34.
5. Paulson RJ, Sauer MV, Francis MM, Macaso TM, Lobo RA. In vitro fertilization in unstimulated cycles: the University of Southern California Experience. Fertil Steril 1992; 57: 290-3.
6. Fauser BC, Devroey P, Yen SS, Gosden R, Crowley WF Jr, Baird DT. et al. Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Hum Reprod 1999; 14: 2681-6.
7. Rongières-Bertrand C, Olivennes F, Righini C et al. Revival of the natural cycle in-vitro fertilization with the use of a new gonadotrophine- releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation. Hum Reprod 1999; 14: 683-8.
8. Jenkins JM, Davies DW, Devonport H, Anthony FW, Gadd SC, Watson RH. et al. Comparison of "poor responders" with "good responders" using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilization. Hum Reprod 1991; 6: 918-21.
9. Land JA, Yarmolinskaya MI, Dumoulin JC, Evers JL High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996; 65: 961-5.
10. Fenichel P, Grimaldi M, Olivero JF, Donzeau M, Gillet JY, Harter M. Predictive value of hormone profiles before stimulation for in vitro fertilization. Fertil Steril 1989; 51: 845-9.
11. Frydman R, Cornel C, de Ziegler D, Taieb J, Spitz IM, Bouchard P. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase. Hum Reprod 1992; 7: 930-3.
12. Ramsewak SS, Kumar A, Welsby R, Mowforth A, Lenton EA, Cooke ID. Is analgesia required for transvaginal single follicle aspiration in in vitro fertilization? A double blind study. J In Vitro Fertil Embryo Transfer 1990; 7: 103-6.
13. Mantoudis E, Podsiadly BT, Gorgy A, Venkat G, Craft IL. A comparison between quarter, partial and total laser assisted hatching in selected infertility patients Hum Reprod 2001; 16: 2182-6.
14. Serafini P, Stone B, Kerin J, Batzofin J, Quinn P, Marrs RP. An alternative approach to controlled ovarian hyperstimulation in "poor responders" with a gonadotrophin releasing hormone analog. Fertil Steril 1988; 49: 90-5.
15. Feldberg D, Farhi J, Ashkenazi J, Dicker D, Shalev J, Ben-Rafael Z. Minidose gonadotropin-releasing hormone agonist is the treatment of choice of poor responders with high follicular stimulating hormone concentrations. Fertil Steril 1994; 62: 343-6.
16. Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994; 61: 880-5.
17. Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L. Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare-growth hormone protocol. Fertil Steril 1997; 67: 93-7.
18. Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW. Clinical and Endocrine Effects of a Microdose GnRH Agonist Flare Regimen Administered to Poor Responders Who Are Undergoing In Vitro Fertilization. Fertil Steril 1998; 69: 419-24.
19. van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod 1993; 8: 369-73.
20. Moreno C, Ruiz A, Simon C, Pellicer A, Remohi J. Intracytoplasmic sperm injection as a routine indication in low responder patients. Hum Reprod 1998; 13: 2126-9.
21. Keay SD, Lenton EA, Cooke ID, Hull MG, Jenkins JM. Low-dose dexamethasone augments the ovarian response to exogenous gonadotrophins leading to a reduction in cycle cancellation rate in a standard IVF programme. Hum Reprod 2001; 16: 1861-5.
22. Liu J, Lu G, Qian Y, Mao Y, Ding W. Pregnancies and births achieved from in vitro matured oocytes retrieved from poor responders undergoing stimulation in in vitro fertilization cycles. Hum Reprod 2003; 80: 447-9.
23. Ledee-Bataille N, Olivennes F, Lefaix JL, Chaouat G, Frydman R, Delanian S. Combined treatment by pentoxifylline and tocopherol for recipient women with a the endometrium enrolled in an oocytes donation programme. Hum Reprod 2002; 5: 1249-53.
24. Stern C, Chamley L, Morris H, Hale L, Baker HW. A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertil Steril 2003; 80: 376-83.
25. Cruz JR, Dubey AK, Patel J, Peak D, Hartog B, Gindoff PR. Is blastocyst transfer useful as an alternative treatment for patients with multiple in vitro fertilization failures? Fertil Steril 1999; 72: 218-20.
26. Aboulghar MA, Mansour RT, Serour GA, Amin YM, Sattar MA, Ramzy AM. In vitro fertilization in a spontaneous cycle: a successful simple protocol. J Obstet Gynacol 1995; 4: 337-40.
27. Lindheim SR, Vidali A, Ditkoff E, Sauer MV, Zinger M. Poor responders to ovarian hyperstimulation may benefit from an attempt at natural-cycle oocyte retrieval. J Assist Reprod Genet 1997; 14: 174-6.
28. Basir GS, Lam TP, O W, Chau MT, Ng EH, Ho PC. Cycle-to-cycle variation in utero-ovarian hemodynamic indices in ovarian stimulation and natural cycles of the same women and its effect on the outcome of assisted reproduction treatment. Fertil Steril 2002; 78: 1055-60.
29. Paulson RJ, Sauer MV, Lobo RA. Embryo implantation after human in vitro fertilization importance of endometrial receptivity. Fertil Steril 1990; 53: 870-4.
30. Edwards RG, Cralf I. Development of assisted conception. Br Med Bull 1990; 46: 565-79.
31. Duckitt K, Templeton A. Cancer in women with infertility. Curr Opin Obstet Gynecol 1998; 10: 199-203.
32. Janssens RMJ, Lambalk CB, Vermeiden JPW et al. In-vitro fertilization in a spontaneous cycle: easy, cheap and realistic. Hum Reprod 2000; 15: 314-318.
33. Lashen H, Ledger W, Lopez-Bernal A et al. Poor responders to ovulation induction:is proceeding to in-vitro fertilization worthwhile? Hum Reprod 1999; 14: 964-9.
34. Ledee-Bataille N, Olivennes F, Kadoch J, Dubanchet S, Frydman N, Chaouat G. et al. Preliminary results: unstimulated IVF cycle: an alternative for patients with repeated unsuccessful IVF-ET and a high uterine NK cell count? Hum Reprod 2003; (sous presse).
35. Nargund G, Waterstone J, Martin Bland J et al. Cumulative conception and live birth rates in natural (unstimulated) IVF cycles. Hum Reprod 2001; 16: 259-62.
36. Olivennes F, Fanchin R, Bouchard P, de Ziegler D, Taieb J, Selva J et al. The single or dual administration of the gonadotrophin-releasing hormone antagonist Cetrorelix in an in vitro fertilization embryo transfer program. Fertil Steril 1994; 62: 468-76.
37. Leroy I, d'Acremont MF, Brailly-Tabard S et al. A single injection of gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fertil Steril 1995; 62: 461-7.
38. Levy D, Navarro J, Schattaman G et al. The role of LH in ovarian stimulation. Hum Reprod 2000; 15: 2258-65.
39. Reichl H, Balen A, Jansen CAM et al. Prion transmission in blood and urine: what are the implications for recombinant and urinary-derived gonadotrophins? Hum Reprod 2002; 17: 2501-8.
40. Cohen J, Alikani M, Trowbridge J, Rosenwaks Z. Implantation enhancement by selective assisted hatching using zona drilling of human embryos with poor prognosis. Hum Reprod 1992; 7: 685-91.